Korro Bio raises $85M in PIPE led by Venrock; cash runway into H2 2028

Korro Bio, Inc.

Gross proceeds ~$85M from 4,501,928 shares at $11.11 and 3,148,836 pre-funded warrants at $11.109.
Preliminary cash, equivalents, marketable securities of $85.2M as of Dec 31, 2025; runway through H2 2028.
Proceeds fund clinical milestones: KRRO-121 for urea cycle disorders and GalNAc-conjugated AATD program.
Closing expected March 10, 2026; placement agents include Citigroup, Cantor, Oppenheimer, William Blair.

item 1.01 item 2.02 item 3.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Korro Bio, Inc. entered into subscription agreement with a number of institutional accredited investors valued at approximately $85.0 million (effective 2026-03-09).

Action: entry
Agreement: equity purchase
Counterparty: a number of institutional accredited investors
Value: approximately $85.0 million
Effective: 2026-03-09

Exact text from the filing

Korro Bio, Inc., or Korro, entered into a subscription agreement with a number of institutional accredited investors pursuant to which it agreed to sell and issue in a private placement

View on SEC.gov

319 material agreements filed in the last 30 days. Browse all material agreements →

Korro Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-097575

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.